Longeveron’s Lomecel-B, an investigational bone marrow-derived medicinal signaling cell (MSC), showed an ability to slow cognitive decline and the loss of daily life abilities in patients with mild Alzheimer’s disease relative to those given a placebo in a Phase 1 clinical trial, the company announced. Treatment with Lomecel-B was deemed safe, with the therapy meeting the trial’s primary safety goal and also improving patients’ quality of life. The levels of several biomarkers for generating new blood vessels and anti-inflammatory…
You must be logged in to read/download the full post.
The post Longeveron’s Stem Cell Therapy Shows Potential in Phase 1 Trial appeared first on BioNewsFeeds.